^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-1β inhibitor

    Related drugs:
    2d
    A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, AbbVie | Trial completion date: Jan 2026 --> Dec 2027 | Trial primary completion date: Jan 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    9d
    CANOPY-1: Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (clinicaltrials.gov)
    P3, N=673, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ilaris (canakinumab)
    12d
    Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. (PubMed, Sci Rep)
    This finding highlights the functional relevance of IMiD's inherent polypharmacology in circumventing primary resistance mechanisms at the cellular level. Together, our results identify the ARID2-containing PBAF complex as a critical vulnerability in resistant myeloma cells and provide a mechanistic rationale for designing combination strategies that co-target this complex, with the potential to enhance therapeutic efficacy by overcoming drug resistance.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • ARID2 (AT-Rich Interaction Domain 2) • IRF4 (Interferon regulatory factor 4)
    |
    pomalidomide • Farydak (panobinostat)
    26d
    Topical Diacerein in Psoriasis Vulgaris (clinicaltrials.gov)
    P4, N=60, Not yet recruiting, Cairo University
    New P4 trial
    27d
    Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    pomalidomide
    1m
    Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users (clinicaltrials.gov)
    P2, N=176, Completed, VA Office of Research and Development | Recruiting --> Completed | N=120 --> 176 | Trial completion date: Jun 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date
    |
    Eyevinal (ibudilast)
    2ms
    REASSURE: Ilaris NIS in Korea (clinicaltrials.gov)
    P=N/A, N=25, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | N=16 --> 25
    Enrollment open • Enrollment change
    |
    Ilaris (canakinumab)
    2ms
    Precision Ferroptosis Amplification via SLC7A11-Directed Proteasomal Degradation for Enhanced Cancer Therapy. (PubMed, Adv Healthc Mater)
    A bifunctional PROTAC, namely dSLC7A11, ws designed by conjugating the SLC7A11 inhibitor sulfasalazine to the CRBN ligand pomalidomide via an alkyl linker. Notably, dSLC7A11 exhibited superior antitumor efficacy over sulfasalazine alone, and achieved an effect of suppressing tumor growth by >65% in vivo. This study presented a SLC7A11-targeting PROTAC that disrupts the cellular antioxidant defense system, thus establishing a novel PROTAC-based approach for potent ferroptosis induction in cancer therapy.
    Journal
    |
    CRBN (Cereblon) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    pomalidomide
    2ms
    Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial (clinicaltrials.gov)
    P2, N=50, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Ilaris (canakinumab)
    2ms
    CD14- CD16+ monocyte PD-L1 prevents early tuberculosis progression and constrains reactivation under immune checkpoint therapy. (PubMed, Front Cell Infect Microbiol)
    Analysis of the FAERS database revealed that the PD-L1 inhibitor durvalumab is significantly associated with TB-related adverse events (reporting odds ratio = 7.81; 95% CI: 4.43-13.78; P = 1.10×10-18)...In silico drug prediction and molecular docking suggested several PD-L1-modulating compounds, including ruthenium, pomalidomide, zidovudine, and lycorine...Together, our findings define a mechanistic axis in CD14- CD16+ monocytes that underpins early TB control and is vulnerable to PD-L1 blockade. Collectively, these findings align with the established notion that assessing latent tuberculosis infection before initiating immune-modulating therapies is essential for minimizing reactivation risk, and propose tractable molecular targets for preventing TB reactivation in immunocompromised hosts.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD14 (CD14 Molecule) • LMO2 (LIM Domain Only 2)
    |
    PD-L1 expression
    |
    Imfinzi (durvalumab) • pomalidomide
    2ms
    Efficacy of melflufen in multiple myeloma with mutated or deleted TP53. (PubMed, Exp Hematol Oncol)
    Post-hoc analysis of the OCEAN trial melflufen-treated del(17p) patient population also demonstrated favorable progression free survival compared to pomalidomide-treated cohort. Our insights into the molecular mechanisms of melflufen activity in TP53-/- myeloma support its clinical efficacy and application in the del(17p) and TP53-/- patient population.Trial registration NCT03151811, registration 2017-05-09.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • Chr del(17p) • TP53 wild-type • TP53 deletion
    |
    pomalidomide • Melflufen (melphalan flufenamide)
    2ms
    Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=25, Completed, University of Chicago | Active, not recruiting --> Completed | N=101 --> 25
    Trial completion • Enrollment change
    |
    Darzalex (daratumumab) • carfilzomib • pomalidomide